Sarah Thompson Schick

Associate

sarah.thompsonschick@dlapiper.com

Austin

T: +1 512 457 7179

F: +1 512 721 2248

Sarah Schick is an associate on DLA Piper's Food and Drug Administration team. She focuses her practice on regulatory matters impacting the life sciences and healthcare industries.

Sarah's practice centers on providing clients with strategic counsel on regulatory matters intersecting with litigation or corporate decision making. She has experience advising on clinical trial issues, contractual matters, compliance programming and risk management.

Prior to joining DLA Piper, Sarah served as in-house counsel for a publicly traded biopharmaceutical company and also gained experience working in the legal department for a large hospital system in Texas. Prior to her legal career, she was involved in clinical trial project management, health outcomes research and healthcare diplomacy.

RELATED SERVICES

- International Trade, Regulatory and Government Affairs
- FDA
- Corporate
- Litigation, Arbitration and Investigations

RELATED SECTORS

- Healthcare
- Life Sciences

EXPERIENCE

- Advising on FDA-regulated matters for initial and follow-on public offerings, mergers and acquisitions, and internal investigations
- Developing and revising contract templates for various clinical agreements including clinical trials, investigator initiated studies, and registries
- Advising on GxP compliance issues, including Good Clinical Practices and Good Manufacturing Practices, relative to clinical trials of investigational and commercial products
- Updating and revising compliance program policies consistent with FDA and HHS-OIG requirements, industry guidelines such as the AdvaMed Code and PhRMA Code, and state-level compliance considerations
- Providing strategic advice on various other matters including Laboratory Developed Tests, FDA marketing application submissions (NDAs, BLAs, 510(k)s), ClinicalTrials.gov registration and compliance, pharmacovigilance and adverse event reporting, advertising and promotion issues, and the Drug Supply Chain Security Act

CREDENTIALS

Admissions

- Texas

Education

- J.D., University of Virginia
  Managing Editor, *Virginia Journal of Law and Technology*
- M.S., Health Systems Management, George Mason University
- B.S., Public Administration, George Mason University

Memberships

- Food and Drug Law Association, BLM Advisory Group
- Healthcare Businesswomen's Association

Civic and Charitable

- United Way for Greater Austin, Board Member
- Congregation Beth Israel (Austin), President-Elect
- Religious Action Center of Reform Judaism, Racial Justice Campaign Leadership Team

INSIGHTS

Publications

Potential paths forward amidst the challenges to COVID-19 therapeutic and vaccine development; collaboration and communication among clinical trial stakeholders takes on heightened importance (United States)

20 March 2020

In a March 19, 2020, briefing and press release, the US Food and Drug Administration outlined ways that existing regulatory options may make it possible to expedite access to therapeutics and vaccines with the potential to treat or prevent coronavirus disease 2019 (COVID-19).

COVID-19: As diagnostic companies and laboratories ask "how can I help?" FDA responds with unprecedented regulatory flexibility, seeking to achieve more rapid testing capacity in the US

18 March 2020
Options expand for life science, healthcare and other stakeholders.

NEWS

DLA Piper names lawyers to Leadership Council on Legal Diversity 2021 Fellows and Pathfinders programs

31 March 2021
DLA Piper is pleased to announce that the firm has selected partner Jamila Willis to participate in the Leadership Council on Legal Diversity's (LCLD) 2021 Fellows Program and has selected associates Mary Hagedorn and Sarah Thompson Schick to participate in the LCLD 2021 Pathfinders Program.

DLA Piper advises Immunomedics in its US$483 million follow-on offering

15 May 2020
DLA Piper represented Immunomedics, Inc., a leading biopharmaceutical company in the area of antibody-drug conjugates, in its recent US$483 million follow-on offering of common stock.
